At Crohn’s & Colitis Congress 2026, a large Mayo Clinic real-world analysis (580 GLP-1–exposed patients) found that patients with ulcerative colitis and Crohn’s disease who used GLP-1s had: Compared with matched IBD patients not on GLP-1 therapy. This was an observational study — so no causality — but the consistency across both UC and Crohn’s suggests a potential anti-inflammatory signal. Bottom line: GLP-1s appear safe in IBD and may even confer benefit, particularly in patients with comorbid obesity or cardiometabolic disease. Prospective studies are needed before positioning them as adjunctive therapy.
Author: Abhay Panchal
The 2025 Identity Theft Resource Center report confirms what many physician-owners are feeling: cyberattacks are no longer random — they’re precise, automated, and increasingly targeted at healthcare. In 2025 alone: This is not “spray-and-pray” ransomware anymore. It’s strategic targeting of patient-record repositories — and private practices are high-value, lower-defense targets.
A recent analysis by healthcare innovation expert Jesse Pines, MD, examines whether the Galleri multi-cancer early detection (MCED) blood test lives up to its promise. Marketed as a simple blood draw capable of detecting over 50 cancers, Galleri analyzes cell-free DNA methylation patterns to identify a “cancer signal” and predict likely tissue of origin. The appeal is obvious: early detection without invasive screening. But the current evidence tells a more nuanced story.
Pathologists Aren’t a Black Box: Why GI–Pathology Communication Directly Impacts Patient Car In a compelling piece in GI & Hepatology News, Dr. Raul S. Gonzalez reminds gastroenterologists of something deceptively simple: pathologists are not diagnostic machines — they are consulting physicians. The article argues that better communication between gastroenterologists and GI pathologists can materially improve diagnostic accuracy, reduce ambiguity, and ultimately enhance patient outcomes. Key takeaways:
Gastroenterology is constantly evolving, with new technologies reshaping care delivery and access as well as the broader patient experience. From AI-driven detection and scheduling to advanced imaging and minimally invasive therapies, the following five innovations are improving outcomes while helping practices manage rising demand, staffing constraints and economic pressure.
Smart toilets are moving from concept to clinical infrastructure. In a recent conversation, Dr. Sonia Grego — Co-Founder & CEO of Coprata and Director of the Duke Smart Toilet Lab — discusses how passive stool analysis could unlock continuous, at-home health insights. Her work focuses on:• Biochemical biomarkers in stool• Sensor-based data capture in everyday settings• AI-driven interpretation• Shifting from episodic testing to longitudinal monitoring If realized at scale, platforms like this could redefine how we think about preventive GI and metabolic care. Worth a listen for anyone tracking the future of digital health and ambient diagnostics.
A multicenter randomized trial in Japan shows that real-time peripheral gaze guidance significantly improves adenoma detection rate (ADR) during colonoscopy — without increasing withdrawal time. In the EYE-SIGHT trial (n=400), patients were randomized to standard colonoscopy or an eye-tracking feedback (ETF) system that prompted endoscopists to scan the periphery of the monitor. Key Results Notably, detection improved for: Advanced adenoma detection and sessile serrated lesion detection did not significantly change.
In a landmark policy effort, the American College of Gastroenterology (ACG) published a modified Delphi consensus outlining how artificial intelligence should be responsibly integrated into GI, hepatology, and endoscopy practice. The paper — Artificial Intelligence for Gastroenterology Practice: A Modified Delphi Consensus — reflects input from 32 experts and 12 industry partners across endoscopy, clinical operations, IBD, liver disease, education, and ethics. What Reached Consensus Endoscopy Clinical Operations IBD & Liver Disease Training & Workforce Governance & Equity The Strategic Signal This is more than a technology endorsement — it is a governance framework. ACG positions AI as augmentative, not…
Basic science continued to advance gastroenterology and hepatology in 2025, offering new insights into disease mechanisms and revealing promising paths for future therapies. Last year’s most-read studies highlight how discoveries at the cellular and molecular level are shaping the way researchers and clinicians think about gut and liver health.
Miami-based startup Cervco has launched a $169 direct-to-consumer Gut-Brain Wellness Test, positioning it as the first at-home assay focused specifically on microbiome markers associated with cognitive wellness. The test analyzes four bacterial targets using digital droplet PCR (ddPCR): Users receive a Gut-Brain Wellness Score (0–100) alongside lifestyle assessments and suggested interventions. No prescription is required. Results are processed in CLIA-certified labs and returned in 2–3 weeks. The Science Signal — and the Caveat Cervco cites emerging research linking specific gut bacteria to pathways involved in inflammation, gut barrier integrity, and neurocognitive function. However: This places Cervco squarely within the rapidly…